What is Gonadorelin? What it does, benefits and what the evidence shows

Gonadorelin is a synthetic copy of gonadotropin-releasing hormone (GnRH), the ten-amino-acid signal the hypothalamus sends to the pituitary to release the hormones that switch on the testes and ovaries. Two human gonadorelin drugs were approved in the US, one for diagnostic testing and one for restoring ovulation, and FDA's database lists both as discontinued. What is still approved and listed on DailyMed is veterinary: injections labeled for cattle. The reason most buyers look for it now is testosterone or anabolic steroid use, and for that specific purpose we found no controlled human trial.

What gonadorelin is and how it works

The label of a veterinary gonadorelin product describes it as a decapeptide, a chain of ten amino acids (DailyMed, Fertagyl label), and Factrel's veterinary label says it has the identical amino acid sequence as endogenous gonadorelin (DailyMed, Factrel label). The Factrel veterinary label says the hormone is produced by the hypothalamus and causes the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (DailyMed, Factrel label). LH is what stimulates the testes to make testosterone and, at mid-cycle, triggers ovulation (DailyMed, Novarel label).

The detail that matters most is the pattern of exposure, not the amount. In rhesus monkeys whose own GnRH release had been wiped out, a constant infusion of GnRH failed to restore normal LH and FSH release, while pulses of the same hormone did restore it; continuous exposure could even shut the response down again (Belchetz et al., Science, 1978). That is why the approved ovulation product delivered gonadorelin in pulses by a pump, and why GnRH-type drugs given in a continuous way behave so differently from a pulsed one.

Gonadorelin acts one step above HCG in the hormone chain. Gonadorelin asks the pituitary to release LH and FSH; HCG is described on its label as acting virtually identically to LH, so it acts on the testes or ovaries directly. Our kisspeptin-10 guide covers another hormone in the same reproductive axis.

US approval status: both human products are discontinued

Here are the primary records, as of September 29, 2026.

• Factrel (gonadorelin hydrochloride injection), NDA 018123. Drugs@FDA shows original approval on September 30, 1982 and lists all three strengths as discontinued (Drugs@FDA, Factrel).
• Lutrepulse (gonadorelin acetate kit), NDA 019687. Original approval October 10, 1989, with orphan status, and both strengths listed as discontinued (Drugs@FDA, Lutrepulse). The multicenter trial behind it tested Lutrepulse for restoring ovulation in women with hypothalamic amenorrhea (Santoro, American Journal of Obstetrics and Gynecology, 1990).
• What is left. A search of DailyMed on September 29, 2026 returned five gonadorelin listings (Factrel, Fertagyl, Cystorelin, Ovacyst and Gonabreed), all from animal-health companies (DailyMed search, gonadorelin). The two labels we opened, Factrel and Fertagyl, are for cattle, and the Factrel one is captioned "For use in cattle only."

FDA's openFDA data feed shows the same two applications with the same discontinued status (openFDA Drugs@FDA data). Drugs@FDA doesn't display labels for either discontinued product, so we can't quote their indications; what they were used for comes from the trial literature below. A 2025 pediatric study noted that native GnRH now has limited availability for stimulation testing, which fits that picture (Sodero et al., Diseases, 2025).

What people use it for

What the research actually shows

Restoring ovulation

The strongest gonadorelin evidence is in women whose own GnRH pulses are absent or weak. In the Lutrepulse multicenter trial of 109 women with primary or secondary hypothalamic amenorrhea, pulsed gonadorelin acetate produced ovulation in 91% of the primary group and 96% of the secondary group. Line-placement complications averaged 7%, multiple pregnancy occurred in 12%, and there was a single case of ovarian hyperstimulation in a woman who also took clomiphene (Santoro, 1990). A later systematic review and meta-analysis of 35 studies (three randomized) covering 1,002 women found high ovulation rates, low and mild ovarian hyperstimulation, and slightly more multiple pregnancies than the general population (Tranoulis et al., 2018). A 25-year Swiss cohort of 66 women with functional hypothalamic amenorrhea reported a 96% ovulation rate per cycle and a live birth rate of 65.9% per treatment (Quaas et al., Journal of Assisted Reproduction and Genetics, 2022). Those are results from specialist-run programs with monitoring, in a specific medical condition.

Men with GnRH deficiency

In a retrospective study of 54 adult men with congenital hypogonadotropic hypogonadism treated with a pulsatile GnRH pump, testicular volume, testosterone and penile length rose significantly over about two years, and 27 of 45 men with sufficient follow-up produced sperm (Jiang et al., 2025). That is a retrospective study without a control group, in men who lack the GnRH signal entirely. It does not tell you what gonadorelin does in a man whose signal is simply turned down by other hormones.

The diagnostic test

GnRH stimulation testing measures how much LH and FSH the pituitary releases after an injection. A 1985 study of healthy people and patients with hypothalamic-pituitary disorders found the test marginally useful for delayed puberty and more useful for hypogonadotropic hypogonadism and true precocious puberty (Dash et al., 1985). A 1976 study of 82 young patients concluded that a severely blunted response in older patients was presumptive evidence of gonadotropin deficiency (Kelch et al., 1976). That is a test: it reads out how a pituitary works, and says nothing about whether repeated injections help anyone.

Testosterone and anabolic steroid users

This is why gonadorelin is on the grey market's radar. Testosterone therapy and anabolic steroids can suppress the brain-to-testes signal, which lowers LH and FSH, reduces the testes' own testosterone output, and impairs sperm production (McBride and Coward, Asian Journal of Andrology, 2016). Buyers look to gonadorelin because it acts on the same pituitary signal.

The evidence for that idea is thin. A 2026 narrative review of peptide and neuroendocrine strategies for testosterone-induced reproductive suppression, including GnRH-related approaches, concluded that direct evidence of restored sperm production or fertility remains limited and that questions about long-term efficacy, safety and treatment protocols are unresolved (Cretu et al., Frontiers in Reproductive Health, 2026). When we searched PubMed on September 29, 2026 for gonadorelin combined with testosterone therapy and testicular outcomes, we found no controlled trial of it. We're not going to tell you how to use it in that setting; the honest summary is that the approved uses were different and the trial evidence for this one isn't there.

Side effects and risks

With no current US human label, safety information has to come from the trials and from the drug's history.

• Ovulation-induction trials. Multiple pregnancy and, rarely, ovarian hyperstimulation; line-placement complications with intravenous pumps (Santoro, 1990). The 2018 meta-analysis also reported superficial thrombophlebitis with intravenous delivery (Tranoulis et al., 2018).
• Purity has come up before. A 1990 paper noted several reports of adverse reactions after pulsatile infusion of gonadorelin hydrochloride and said the contribution of impurities and degradation products had not been determined; the authors suggested that high-purity material may help control unwanted effects (Wong et al., International Journal of Fertility, 1990). That paper tested the purity and stability of one company's gonadorelin acetate product (Lutrepulse) and did not show that impurities caused the reactions, but it is a reminder that a vial's contents matter.
• Unknowns. We found no long-term safety data for self-directed gonadorelin use in healthy men, and no human label to point to. Veterinary products are labeled for cattle only.
• Pattern matters. In monkeys, continuous rather than pulsed GnRH exposure could shut the pituitary response down (Belchetz et al., 1978). That is animal work, but it is why this hormone can't be assumed to work like a simple on-switch.

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for gonadorelin. That doesn't mean vials are good or bad; it means no report has been submitted that we can count. If you have had a gonadorelin vial tested, submitting the report is the fastest way to change that.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, lean on the general checks. Look at each vendor's full record and how many reports sit behind the score. Treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). For a compound with no track record in our data, paying for identity, purity and quantity testing on your own vial is worth it; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Related reading: HCG, kisspeptin-10, sermorelin, and the peptide hub.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; gonadorelin sold outside a licensed setting is unregulated and sold for research use only, and its US human drug products are discontinued.